Lessons From A Life Sciences Lifetime: An Interview With Sir John Bell
Professor Sir John Bell talks to In Vivo about how the life sciences sector has evolved during his career, lessons he has learned along the way, and the biggest challenges and changes ahead for the industry in 2019.
You may also be interested in...
Several major global health-care diagnostics groups have won bids to spearhead five new UK centers of excellence for digital pathology and imaging, including radiology and using AI medical advances. A key aim of the initiative, provided for under the UK Life Sciences Industrial Strategy, is to create a brand new commercial sector around the development of AI for diagnostics, says Neil Mesher, CEO of Philips UK and Ireland, which has a role in two of the centers.
The UK government has finally published its Industrial Strategy white paper, which includes a “sector deal” for the life sciences that promises “substantial” private and charitable sector investments.
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.